Table 3 Primary endpoint comparison within treatment groups for the management of hypertension in neurocritical patients.

From: The safety and efficacy of clevidipine for blood pressure management in neurocritical patients: a systematic review and meta-analysis

Study ID

Time to achieve target SBP, hours

Percentage of time in target SBP range, %

Achieved systolic blood pressure goal, n

Clev

Control

Clev

Control

Clev

Control

Borrell-Vega 2020

29.6 ± 11.1

52.1 ± 17.7

90.8 ± 8.3

74.7 ± 12.9

n.r

n.r

Finger 2016

34 ± 12

52.6 ± 22.5

79.2 ± 6.8

77.9 ± 7.3

8

15

Rosenfeldt 2018

n.r

n.r

65.8 ± 101

65.5 ± 108.2

30

26

Rodriguez 2022

71 ± 48

N/A

64 ± 89

N/A

75 out of 103 patients, no control group

Allison 2017

Reported in 2- and 24-h period

80 ± 19

75 ± 19

AIS = 12 vs 16 patients; ICH: 21 vs 17 patients

  1. Clev clevidipine, n number, N/A not applicable, n.r not reported, SBP systolic blood pressure.
Back to article page